Impact of Piperacillin/Tazobactam on Nephrotoxicity in Patients with Gram-negative Bacteremia

This study aims to evaluate piperacillin/tazobactam's impact on nephrotoxicity in patients with GNB. Our retrospective cohort included patients ≥18 years of age who received ≥48 hours of therapy for bacteremia due to Escherichia coli, Pseudomonas aeruginosa, Enterobacter sp., Klebsiella sp., Acinetobacter sp., or Stenotrophomonas maltophila from 1/1/2008-8/31/2011.

Source: International Journal of Antimicrobial Agents - November 8, 2018 Category: Drugs & Pharmacology Authors: Ronald G. Hall, Eunice Yoo, Andrew Faust, Terri Smith, Edward Goodman, Eric M. Mortensen, Jaffar Raza, Farbod Dehmami, Carlos A. Alvarez Tags: Short Communication Source Type: research